Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Here’s Why

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP) gapped up prior to trading on Monday. The stock had previously closed at $28.22, but opened at $29.21. Spyglass Pharma shares last traded at $29.25, with a volume of 3,202 shares traded.

Analysts Set New Price Targets

Several research firms have commented on SGP. UBS Group restated a “buy” rating on shares of Spyglass Pharma in a research report on Monday, October 5th. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Spyglass Pharma in a research report on Wednesday, October 21st. Wall Street Zen cut Spyglass Pharma from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Weiss Ratings downgraded shares of Spyglass Pharma from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday, September 25th. Finally, Raymond James Financial assumed coverage on shares of Spyglass Pharma in a research report on Friday, August 14th. They set an “outperform” rating and a $39.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Spyglass Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Spyglass Pharma Stock Up 5.0%

The firm has a fifty day moving average of $26.74 and a 200-day moving average of $23.40. The stock has a market capitalization of $999.22 million and a price-to-earnings ratio of -4.27.

Spyglass Pharma (NASDAQ:SGP) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). As a group, research analysts forecast that Spyglass Pharma, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Spyglass Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC purchased a new stake in Spyglass Pharma in the first quarter valued at approximately $9,716,000. Affinity Asset Advisors LLC acquired a new position in shares of Spyglass Pharma in the 1st quarter worth approximately $6,478,000. Monashee Investment Management LLC acquired a new stake in shares of Spyglass Pharma during the 1st quarter valued at approximately $2,461,000. Bank of America Corp DE bought a new position in Spyglass Pharma during the first quarter worth $726,000. Finally, Bank of New York Mellon Corp bought a new stake in Spyglass Pharma during the second quarter valued at $533,000.

Spyglass Pharma Company Profile

SpyGlass Pharma, Inc is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company’s platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.

SpyGlass Pharma’s lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.

The company is advancing its technology through clinical development and regulatory processes in the United States.